AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Quest Diagnostics Partners with Fujirebio to Offer Alzheimer's Diagnostic Test
ByAinvest
Wednesday, Jul 9, 2025 4:38 pm ET1min read
Quest Diagnostics plans to introduce a new laboratory test using Fujirebio's Lumipulse diagnostic technology to identify patients with amyloid pathology linked to Alzheimer's disease. The company aims to provide this test to healthcare professionals to aid in diagnosing and managing Alzheimer's.
Quest Diagnostics (NYSE: DGX) has announced plans to introduce a new laboratory test using Fujirebio's Lumipulse diagnostic technology to identify patients with amyloid pathology linked to Alzheimer's disease. The company aims to provide this test to healthcare professionals to aid in diagnosing and managing Alzheimer's.The new test, based on the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. Quest Diagnostics plans to make the test available to physicians and biopharmaceutical collaborators later this summer.
The test is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. In a clinical study population of 499 patients, which closely mirrors US demographics, the FDA-cleared test demonstrated a positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 97%, with 20% of patients requiring further testing.
Quest Diagnostics, which provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease through its AD-Detect™ portfolio, will extend this portfolio to include the Fujirebio test offering. This addition will provide healthcare professionals with another powerful option for assessing patients for Alzheimer's disease.
Quest Diagnostics will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31.
References:
[1] https://www.prnewswire.com/news-releases/quest-diagnostics-to-offer-fda-cleared-fujirebio-blood-test-for-alzheimers-disease-302500634.html
[2] https://www.patientcareonline.com/view/quest-will-offer-fda-cleared-fujirebio-blood-test-to-detect-alzheimer-disease
[3] https://www.stocktitan.net/news/DGX/quest-diagnostics-to-offer-fda-cleared-fujirebio-blood-test-for-mbvoeb77fy1a.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet